Tirofiban HCl
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 598044

CAS#: 142373-60-2 (HCl)

Description: Tirofiban HCl is a platelet glycoprotein-IIb/IIIa receptor antagonist.


Chemical Structure

img
Tirofiban HCl
CAS# 142373-60-2 (HCl)

Theoretical Analysis

MedKoo Cat#: 598044
Name: Tirofiban HCl
CAS#: 142373-60-2 (HCl)
Chemical Formula: C22H37ClN2O5S
Exact Mass: 476.21
Molecular Weight: 477.050
Elemental Analysis: C, 55.39; H, 7.82; Cl, 7.43; N, 5.87; O, 16.77; S, 6.72

Price and Availability

Size Price Availability Quantity
10mg USD 270
50mg USD 800
Bulk inquiry

Related CAS #: 150915-40-5 (HCl hydrate)   144494-65-5 (free base)    

Synonym: Tirofiban hydrochloride; Tirofiban HCl; MK 383; MK-383; MK383; Aggrastat; L 700462; L-700462; L700462;

IUPAC/Chemical Name: (S)-2-(butylsulfonamido)-3-(4-(4-(piperidin-4-yl)butoxy)phenyl)propanoic acid hydrochloride

InChi Key: KPKFFYOMPGOQRP-BOXHHOBZSA-N

InChi Code: InChI=1S/C22H36N2O5S.ClH/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18;/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26);1H/t21-;/m0./s1

SMILES Code: O=C(O)[C@H](CC1=CC=C(OCCCCC2CCNCC2)C=C1)NS(=O)(CCCC)=O.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 477.05 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Bergquist PA, Hunke WA, Reed RA, Manas D, Forsyth RJ, Kenney RR, Cook J, Holahan M. Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration. J Clin Pharm Ther. 1999 Apr;24(2):125-32. PubMed PMID: 10380064.

2: Saucedo JF, Garza L, Wolford DC, Cook SL, Ramanathan KB, Matin Z, McGrew FA, Jacoski MV, Jennings LK; Tennessee-Arkansas-Mississippi (TAM) Clinical Research Consortium. Comparative pharmacodynamic evaluation of eptifibatide and tirofiban HCl in patients undergoing percutaneous coronary intervention (the TAM1 Study). Am J Cardiol. 2004 May 15;93(10):1279-82. PubMed PMID: 15135704.

3: Yates YJ, Farias CL, Kazmier FR, Puckett CL, Concannon MJ. The effect of tirofiban on microvascular thrombosis: crush model. Plast Reconstr Surg. 2005 Jul;116(1):205-8. PubMed PMID: 15988269.

4: El-Bagary RI, Elkady EF, Farid NA, Youssef NF. Validated spectrofluorimetric methods for the determination of apixaban and tirofiban hydrochloride in pharmaceutical formulations. Spectrochim Acta A Mol Biomol Spectrosc. 2017 Mar 5;174:326-330. doi: 10.1016/j.saa.2016.11.048. Epub 2016 Dec 3. Erratum in: Spectrochim Acta A Mol Biomol Spectrosc. 2017 Jun 15;181:23. PubMed PMID: 27984753.

5: Jennings LK, Jacoski MV, White MM. The pharmacodynamics of parenteral glycoprotein IIb/IIIa inhibitors. J Interv Cardiol. 2002 Feb;15(1):45-60. Review. PubMed PMID: 12053684.

6: Proimos G. Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors. J Thromb Thrombolysis. 2001 Apr;11(2):99-110. Review. PubMed PMID: 11406724.

7: Dyke CM. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective. Am Heart J. 1999 Oct;138(4 Pt 2):307-16. Review. PubMed PMID: 10502236.